Field Name	Field Description
Prior Authorization Group Description	Lamzede
Drugs	Lamzede (velmanase alfa-tycv)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	N/A
Required Medical Information	"See Other Criteria"
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist in the treatment of alpha-mannosidosis or other lysosomal storage disorders
Coverage Duration	If all of the criteria are met, the request will be approved for 12 months

Other Criteria
 	
Revision/Review Date 4/2024
	****Drug is being requested through the member's medical benefit****
	
	Initial Authorization
	• Diagnosis of alpha-mannosidosis as confirmed by one of the following:
	  o Deficiency in alpha-mannosidase enzyme levels or activity in blood leukocytes
	  o DNA testing
	• Prescriber attests that medication will only be used to treat non-central nervous system manifestations of alpha-mannosidosis
	• Patient's weight
	• Dosing is consistent with FDA-approved labeling or is supported by compendia or standard of care guidelines
	
	Reauthorization
	• Patient has demonstrated a clinical response (i.e., reduction in serum oligosaccaride concentrations, stabilization or improvement in 3-minute stair climbing test [3MSCT], 6-minute walking test [6-MWT], forced vital capacity [FVC], etc.)
	• Prescriber attests that medication will only be used to treat non- central nervous system manifestations of alpha-mannosidosis
	• Patient's weight
	• Dosing is consistent with FDA-approved labeling or is supported by compendia or standard of care guidelines

	Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.